Enzymatic properties of the N- and C-terminal halves of human hexokinase II. by 源�醫낆꽑 et al.
BMB
   reports
350 BMB reports http://bmbreports.org
*Corresponding author. Tel: 82-2-2228-2366; Fax: 82-2-312-0578;
E-mail: jdlee@yuhs.ac
Received 8 January 2009, Accepted 9 February 2009
Keywords: Conformation, Deletion mutant, Hexokinase II, Kinetics 
properties, 18F-FDG
Enzymatic properties of the N- and C-terminal halves of 
human hexokinase II
Keun Jae Ahn1, Jongsun Kim2, Mijin Yun1, Jeon Han Park2 & Jong Doo Lee1,*
1Division of Nuclear Medicine, Department of Diagnostic Radiology, Research Institute of Radiological Science, 2Department of 
Microbiology, Yonsei University College of Medicine, Seoul 120-752, Korea
Although previous studies on hexokinase (HK) II indicate both 
the N- and C-terminal halves are catalytically active, we show 
in this study the N-terminal half is significantly more catalytic 
than the C-terminal half in addition to having a significantly 
higher Km for ATP and Glu. Furthermore, truncated forms of in-
tact HK II lacking its first N-terminal 18 amino acids (Δ18) and 
a truncated N-terminal half lacking its first 18 amino acids 
(Δ18N) have higher catalytic activity than other mutants tested. 
Similar results were obtained by PET-scan analysis using 18F- 
FDG. Our results collectively suggest that each domain of HK 
II possesses enzyme activity, unlike HK I, with the N-terminal 
half showing higher enzyme activity than the C-terminal half. 
[BMB reports 2009; 42(6): 350-355]
INTRODUCTION
In humans,  hexokinase (HK, EC 2.7.1.1) types I, II, III, and IV 
are four distinct enzymes with different properties and tissue 
distribution, and are responsible for glucose phosphorylation 
(1, 2). Besides having a high affinity for glucose, HKs I-III have 
a molecular mass of 100 kDa and are regulated by feed-
back-inhibition in response to the physiologic concentration of 
glucose 6-phosphate (G6P). In contrast, hexokinase IV (HK IV 
or glucokinase) is a 50 kDa protein with a lower affinity for 
glucose and is not inhibited by physiologic concentrations of 
G6P, similar to the 50 kDa yeast enzyme (3, 4). Interestingly, 
100 kDa HK isozymes exhibit internal sequence repetition as 
evidenced by extensive sequence similarity between the N-ter-
minal and the C-terminal halves of the enzymes, which are 
similar to sequences present in 50 kDa hexokinases (1, 2, 5). 
Therefore, a widely-accepted hypothesis supported by the high 
degree of amino acid similarity both between the N- and C-ter-
minal halves of a given HK and between glucokinase and 
yeast HK (6, 7) is that the 100-kDa isoforms are derived from a 
50-kDa precursor through gene duplication and tandem liga-
tion (1).
    Many studies confirm marked functional differences be-
tween the N- and C-terminal halves of HK I despite sharing 
similar amino acid sequences. In particular, the C-terminal half 
of HK I is catalytically active versus an inactive N-terminal half 
(8, 9). Although G6P binds to both halves of HK I, the G6P 
regulatory site of HK I is located in the N-terminal half of the 
intact enzyme whereas the C-terminal binding site is inactive 
(1, 8). Wilson suggested this latency of high affinity in the G6P 
binding site of the C-terminal half is due to steric interference 
caused by the corresponding N-terminal region (10). Gelb et 
al. (11) showed that the 15 amino acids belonging to the N-ter-
minus of hexokinase are sufficient to target a reporter se-
quence to rat liver mitochondria. Moreover, the first 11 N-ter-
minal amino acids are very hydrophobic and may influence 
the specific activity of HK I (12, 13). Recent studies show both 
the N- and C-terminal halves of human and rat HK II (N-HK II 
and C-HK II, respectively) possess catalytic activity and are in-
hibited by G6P (14, 15). However, the kinetic characteristics 
of the N- and C-terminal halves of HK II widely differ: N-HK II 
has a slightly higher affinity for ATP than does C-HK II, and its 
Ki for G6P is approximately 20-30-fold lower than that of 
C-HK II (3).
    In past years, the high sensitivity and specificity of 18F-FDG 
PET has promoted its wide use in the field of clinical 
oncology. Cancer cell growth is heavily dependent on glucose 
metabolism as a major energy source and therefore the 
18F-FDG uptake pattern in PET scans reflects cellular glycolytic 
activity. In this study, we investigated the enzymatic character-
istics of the N- and C-terminal halves of HK II using a series of 
deletion mutants. We also addressed glucose uptake and me-
tabolism using FDG-PET in transiently-transfected cells ex-
pressing mutant HK enzymes.
RESULTS
Expression of truncated human HK II
HKs I-III contain two regions, the N-terminal regulatory region 
(residues 1-475) and the C-terminal catalytic region (residues 
476-917), which share high sequence homology. In HK II, the 
N-terminal region contains a hydrophobic, 12 amino acid 
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Fig. 1. Expression profile of HK II in SNU449 cell lines. (A) Schematic
diagram of HK II and deletion mutant constructs. Full-length (HK II),
a truncated form lacking the first N-terminal 18 amino acids (Δ18), 
the N-terminal half of hexokinase (N-term), a truncated form of N-term
lacking the first 18 amino acids (Δ18N) and the C-terminal half of hex-
okinase (C-term). (B) Western blot analysis of overexpressed HKII and
deletion mutants. SNU449 cells were transiently transfected with 
HKII, N-term, C-term, Δ18 and Δ18N constructs. Cell lysates were pre-
pared 3 days after transfection. Densitometric data: His/α-tubulin ratio:
HK II = 1.15 ± 0.04, N-term = 1.17 ± 0.03, C-term = 1.15 ± 0.07,
Δ18 = 1.16 ± 0.02, Δ18N = 1.15 ± 0.06; P ＜ 0.01, n = 5.
Over-expressed 
recombinant protein Specific activity Km (glucose) Km (ATP) Ki (G6P)
Units/mg* mM
HK II 
N-term 
C-term 
Δ18 
Δ18N 
7.39 ± 0.14
4.77 ± 0.07
1.13 ± 0.17
7.74 ± 0.09
4.83 ± 0.14
0.37 ± 0.12
0.4 ± 0.06
0.64 ± 0.07
0.35 ± 0.05
0.38 ± 0.04
0.81 ± 0.11
0.67 ± 0.07
3.61 ± 0.1
0.79 ± 0.12
0.6 ± 0.14
0.24 ± 0.06
0.13 ± 0.04
2.51 ± 0.2
0.25 ± 0.04
0.18 ± 0.06
*Units/mg is the protein amount that was used after calculating for molar ratio of the protein’s molecular weight.
Table 1. Kinetic constants of recombinant hexokinase II, N-terminal half, C-terminal half, Δ18 and Δ18N
chain. To investigate which region is responsible for the en-
zyme activity of HK II, we compared the full-length enzyme 
(HK II) with four deletion mutant constructs: a truncated form 
lacking the first N-terminal 18 amino acids (Δ18), the N-termi-
nal half of hexokinase (N-term), a truncated form of N-term 
lacking the first 18 amino acids (Δ18N), and the C-terminal 
half of hexokinase (C-term) (Fig. 1A). Purification was designed 
based on a 5X histidine motif added to the carboxy-terminus of 
each protein, which also reduced the degree of conformational 
change. The protein samples used in this study were found to 
be highly pure, as determined by SDS-PAGE and western blot-
ting (Supplemental Material 1). We first investigated the enzy-
matic activity of each purified HK II deletion mutant and found 
expression of HK II, N-term, and C-term was associated with 
glucose phosphorylating activity (Table 1). Notable results 
found enzyme activity of the N-terminal half was higher than 
the C-terminal half and that Δ18 and Δ18N both have higher 
specific enzyme activity than their intact counterparts, HK II or 
N-term. Previous studies showed removal of the hydrophobic 
N-terminal 11 amino acids from HK I increases its enzyme ac-
tivity (12). These observations support earlier speculation that 
the larger isoforms arose originally via duplication and tandem 
fusion of an ancestral ∼50 kDa hexokinase precursor (16, 17). 
The kinetic properties of these deletion mutants are also 
shown in Table 1. The C-terminal half of HK II has a lower en-
zyme activity than the other deletion constructs. Regarding 
specific activity, N-term, C-term and Δ18N have comparable 
levels, although still lower than the intact enzyme and the Δ18 
construct. In addition, C-term has a slightly lower affinity for 
glucose compared to the similar Km values shared by HK II, 
N-term, Δ18 and Δ18N. C-term also had a significantly lower 
affinity for ATP than the other mutants. Based on this experi-
ment, we concluded that contrary to HK I the N-terminal re-
gion of HK II has higher enzyme activity than in its C-terminal 
region. In addition, the hydrophobic region of the N-terminus 
influences enzyme activity.
Kinetic parameters of N-term, C-term, and Δ18N constructs
As noted previously, the N- and C-terminal halves of HK II dis-
play a greater degree of similarity than in HK I or III (60% 
compared with 51% and 47%, respectively), suggesting HK II 
is more closely related to the original 100-kDa hexokinase 
than either HK I or III. Therefore, we compared the N- and 
C-terminal sequences of from each HK and specifically com-
pared each domain (Supplemental Material 2). Sequence sim-
ilarities between the N- and C-terminal halves of HK II 
(55.37% identical; 20.21% strongly similar, and 6.11% weakly 
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Fig. 2. Measurement of 18F-FDG uptake levels in transiently trans-
fected cells. (A) Uptake of 8F-FDG by cells expressing HKII, N-term, 
C-term, Δ18 and Δ18N in comparison with wild-type cells (con). 
Uptake values are expressed as mean ± standard deviation of three
independent experiments (n = 4). *P ＜ 0.05; **P ＜ 0.01; ***P
＜ 0.001. (B) Cellular uptake of 18F-FDG.
similar) are more extensive than for either HK I or III. Kinetic 
parameters showed the N-term and Δ18N constructs contain 
significantly higher affinities for ATP than the C-term construct 
(Table 1) yet also significantly lower Ki values for G6P. In ad-
dition, the first 18 N-terminal amino acids influence the specif-
ic activity of HK II.
Different truncated forms of human HK II in intact cells 
The positron-labeled glucose analogue 18F-FDG, which is 
transported into cells, phosphorylated, but undergoes little fur-
ther metabolism, is utilized in cancer imaging to identify in-
creased glucose uptake in tumor cells by detecting accumu-
lated FDG with positron emission tomography (PET) (18). 
Therefore, to investigate activity of the HK mutants within cells 
we inserted the mutant genes into eukaryotic expression vec-
tors and added a histidine motif at the carboxy-terminus of 
each protein to confirm successful transfection. We first identi-
fied a cell line with low levels of HK II expression. As shown 
in Fig. 1B, successful transfection of each mutant was con-
firmed by western blot analysis. We then investigated the en-
zyme activity of the various mutants by comparing the 
18F-FDG uptake patterns on media containing various glucose 
concentrations after transient transfection. As shown in Fig. 
2A, the FDG phosphorylation efficiency of HK II appears to be 
slightly different than the other mutants. Only small differ-
ences in efficiency between the mutants were observed under 
high glucose conditions, and similar results were obtained 
with the purified recombinant proteins. However, more sig-
nificant differences in 18F-FDG uptake were observed between 
the mutants under conditions of low glucose. Uptake of 
18F-FDG was highest in HK II, followed by the N-term, Δ18 
and Δ18N constructs. Both Δ18 and Δ18N demonstrated high-
er intensity compared to their respective intact forms. In con-
trast, despite high FDG phosphorylation efficiency in vitro, the 
C-term mutant displayed decreased 18F-FDG uptake compared 
with the other mutants. Similar results were obtained in 
FDG-PET scans (Fig 2B).
    These results indicate the enzyme activity of the C-terminus 
in vivo is lower than the N-terminus. Furthermore, the 18 ami-
no acids at the end of the HK II N-terminus slightly increased 
enzyme activity in vivo.
DISCUSSION
One of the most important functions of mammalian HK en-
zymes I-IV is the phospholylation of glucose during glycolysis. 
The extensive amino acid sequence similarity between the N- 
and C-terminal halves of the 100-kDa hexokinases indicates 
that these proteins evolved from an ancestral 50-kDa, 
yeast-like hexokinase by a process of gene duplication and 
gene fusion (16, 19). Interestingly, despite sharing high se-
quence homology and very similar glucose and ATP binding 
domains, the two halves differ in enzymatic activity, Km values 
for ATP and glucose and Ki values for G6P. Indeed, evidence 
has accumulated in recent years proposing the N- and C-termi-
nal halves of HK I have a marked functional difference despite 
the similarity of their amino acid sequences. Although, the N- 
and C-terminal halves of HK I have individually retained the 
ability to bind both glucose and G6P at distinct sites (8, 20), 
the catalytic activity of HK I is functionally restricted to its 
C-terminal half (9, 11, 21). In contrast, both the N- and C-ter-
minal halves of HK II possess intrinsic catalytic activity (3, 15, 
22). In addition, the intact and N-terminal half of HK II possess 
significantly higher affinities for ATP and G6P than the C-ter-
minal half does. In this study, we demonstrated the N-terminal 
half (amino acid residues 1-475) provides the major enzyme 
activity of HK II while the C-terminal half (amino acid residues 
476-917) has lower enzyme activity. Similar to HK I, specific 
activity of HK II appears mediated by the mitochondrial bind-
ing domain (amino acid residues 1-18) at its N-terminus. 
Furthermore, the N-terminal and Δ18N constructs show higher 
affinity for ATP than the C-terminal half.
    Many lines of evidence suggest either GST or the GST-do-
mains of fusion proteins have the potential to mediate oligo-
merization both in vitro and in vivo (23, 24). In particular, 
Tudyka and Skerra mentioned that one should remember 
many proteins require an intact N-terminus for their bio-
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chemical activity when considering the use of GST as a perma-
nent rather than transient fusion partner (24). Regarding hydro-
phobicity, previous studies have shown the first 12 N-terminal 
amino acids of HK II (the mitochondrial binding domain) 
along with the first 11 N-terminal amino acids of HK I are very 
hydrophobic and may influence the kinetic properties of the 
enzyme (12).  Therefore, difficulties are associated with meas-
uring the biochemical activity of either HK II or its mutants us-
ing the GST fusion system. In addition, the shape of the active 
site that binds the substrate is very important and could be 
problematic when masking or conformational changes occur 
during GST fusion in enzyme function studies. TO minimize 
such effects, we therefore decided to add a 5X histidine to the 
C-terminus of each recombinant protein to maintain the native 
conformation of the enzyme. We found that during protein pu-
rification the hydrophobic moieties of HK II and its N-terminal 
half were very unstable and denatured rapidly compared with 
the C-terminal half, Δ18, or Δ18N contructs. These results sug-
gest the first 18 amino acids not only affect the enzyme activ-
ity of HK II, but also contribute to the stability of the enzyme.
    18F-FDG PET is becoming a routine clinical procedure for 
tumor detection by exploiting the enhanced utilization of glu-
cose exhibited by tumor cells compared with normal cells 
(25). HKs are the first rate-limiting enzymes of the glycolytic 
pathway and therefore play a pivotal role in 18F-FDG uptake 
and glycolytic pathways in malignant cells. We examined 
18F-FDG uptake in SNU-449 HCCs transiently transfected with 
full-length HK II and each mutant construct. Additionally, we 
controlled the glucose level in the media and investigated the 
sensitivity of each mutant. The FDG uptake pattern within the 
cell correlates with the results obtained for the purified 
protein. In vitro examination of the C-terminal half showed rel-
atively high levels of FDG phosphorylation, likely due to addi-
tional FDG uptake mediated by Glut-1. 
    In contrast to HK I, each domain of HK II possesses enzyme 
activity with the N-terminal half showing higher enzyme activ-
ity than the C-terminal half. In addition, the first 18 N-terminal 
amino acids influence the specific activity of HK II.
MATERIALS AND METHODS
Materials
Leupeptin, pepstatin, phenylmethylsulfonyl fluoride (PMSF) and 
imidazole were purchased from Boehringer Manheim (Manheim, 
Germany). Glucose, Leuconostoc mesentroides glucose-6-phos-
phate dehydrogenase (G6PD) and adenosine triphosphate (ATP, 
disodium salt) were obtained from Roche Chemical Company 
(Mannhein, Germany). Nicotinamide adenine dinucleotide 
(NAD+, disodium salt) was obtained from Fluka Chemical 
Company (Buchs, Switzerland), and Ni-NTA resin, b-D-thio-
galactopyranoside (IPTG), 4-(2-hydroxyethyl)-1- piperazineethane 
sulfanic acid (HEPES) buffer and dithioerythritol (DTE) were 
purchased from Sigma Chemical Company (St. Louis, MO).
Construction of expression vectors for HK II and the deletion 
mutants
The protein-coding regions of full-length (HK II) and the N-ter-
minal half (N-term) of HK II were amplified by PCR using the 
5'-oligonucleotide primer CGAGCTCCATATGATTGCCTCGC 
ATCTGCT, containing the underlined Nde I restriction site, 
and the 3'-oligonucleotide primers CGGAATTCTTAATGATGA 
TGATGATGTCGCTGTCCAGCCT and CGGAATTCTTAATGA 
TGATGATGATGCTCTAATGT, containing the underlined EcoRI 
restriction site. Truncated protein-coding regions of HK II lack-
ing the first N-terminal 18 amino acids (Δ18) and its N-termi-
nal half lacking the first 18 amino acids (Δ18N) were amplified 
by PCR with the 5'-oligonucleotide primer ATTCCATATGGTG 
CAGAAGGTTGACC, containing the underlined Nde I restric-
tion site, and the 3'-oligonucleotide primers CGGAATTCTTAA 
TGATGATGATGATGTCGCTGTCCA and CGGAATTCTTAAT 
GATGATGATGATGCTCTAATGT, containing the underlined 
EcoRI restriction site. The protein-coding region of the HK II C- 
terminus (C-term) was amplified by PCR with the 5'-oligonu-
cleotide primer ATTCCATATGGTGCAGAAGGTTGACC, con-
taining the underlined Nde I restriction site, and the 3'-oligo-
nucleotide primers CGGAATTCTTAATGATGATGATGATGTC 
GCTGTCCA, containing the underlined EcoRI restriction site. 
PCR amplification products were gel purified, digested with 
the appropriate restriction enzymes and cloned into the pRSET 
A bacterial expression vector (Invitrogen). To generate mam-
malian expression plasmids, DNA corresponding to full length 
HK II and each deletion mutant was isolated from pRSET A us-
ing Nde I/Klenow and EcoRI and ligated into pcDNA 3.1/Myc- 
His (Invitrogen, CA, USA), followed by digestion with EcoRV 
and EcoRI. All constructs were confirmed by DNA sequencing.
Bacterial expression and purification of mutant proteins
HK II deletion mutants were overexpressed in Escherichia coli 
BL21 followed by purification of recombinant proteins to ap-
parent homogeneity using Ni-NTA resin, according to the 
manufacturer’s instructions (Sigma). Protein concentration was 
determined with the BCA assay kit (Pierce, Rockford, IL) ac-
cording to the manufacturer’s recommendations, using bovine 
serum albumin as a protein standard. Protein samples were 
stored at −30oC until use.
Cell culture
Human hepatocelluar carcinoma (HCC) cells were obtained 
from the Korean Cell Line Bank (Seoul, Korea) and maintained 
in RPMI 1640 medium supplemented with 10% fetal bovine 
serum (FBS) and penicillin-streptomycin in a humidified atmos-
phere of 5% CO2 at 37oC. Cells were maintained in low (1 g/L) 
glucose medium for 16 h and then cultured in either low or 
high (4.5 g/L) glucose medium for an additional 24 h.
Transient transfection
Transient transfections were performed using the cationic lipid 
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Lipofectamine 2,000 (Invitrogen) according to the manufactur-
er's specifications. Expression of recombinant protein was con-
firmed by western blot analysis with anti-HisTag antibodies. 
Cells were allowed to recover in RPMI 1,640 for 24-72 h after 
transfection before use in experiments.
Western blot analysis
Western blot analyses were performed using an anti-HK II anti-
body (AB3279 Chemicon, Temecula, CA, USA) and an anti-HisTag 
antibody (Qiagen, Hilden, Germany), respectively, and visualized 
using an ECL-detection system (Pierce, Rockford, IL), followed by 
exposure to photographic film. Relative protein expression levels 
were calculated based on X-ray film densitometry data (ChemiI-
mager 5500 software, Alpha Innotech) after normalization with 
the respective housekeeping α-tubulin signals.
18F-FDG uptake
For radiotracer uptake experiments, cells were plated in 24 
well plates at a density of 5 × 104 cells/well (Greiner, Fricken-
hausen, Germany). 18F-FDG uptake was determined by incu-
bation with fresh medium containing 185 kBq (5 μCi) 18F-FDG/ 
mL for 30 min at 37oC. PET imaging was performed using a 
whole-body PET camera (Advance Tomograph; GE Healthcare). 
Cell lysates were counted with a Cobra II gamma counter 
(Canberra-Packard, Meriden, CT, USA). 
Measurement of hexokinase activity
Hexokinase activity was determined spectrophotometrically in 
which glucose 6-phosphate formation is coupled to NADPH 
production in the presence of excess glucose 6-phosphate 
dehydrogenase. The process is monitored at 340 nm. One unit 
of HK activity is defined as the amount of enzyme that cata-
lyzes the production of 1 μmol of G6P or ADP per minute at 
30oC. Kinetic parameters were determined using Lineweaver- 
Burke and Eadie-Hofstee analyses, with Km determined using 
at least five experiments, as described previously (26, 27).
Measurement of total cellular hexokinase activity
Total cellular hexokinase activity was measured using the 
Vinuela method as modified by Waki et al (28, 29). Hexokinase 
activity was determined from a standard curve, with 1 unit de-
fined as the enzyme activity that phosphorylates 1 μmol/L of glu-
cose per minute at 20oC. Aliquots were removed to measure pro-
tein content, and the enzyme activity was expressed as mU/mg 
protein.
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